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Repeated cycles of retrovirus-mediated HSVtk gene
transfer plus ganciclovir increase survival of rats with
peritoneal carcinomatosis
F Princen1, C Lechanteur1, M Lopez1, G Rocoux2, B Detroz2, J Gielen1, G Fillet1, M-P Merville1
and V Bours1
1Laboratory of Medical Chemistry and Medical Oncology, and 2Department of Abdominal Surgery, University of Lie`ge, Belgium
Peritoneal carcinomatosis is a common clinical situation followed by a 4–5-day course of ganciclovir treatment,
that requires novel therapeutic approaches. We investi- showed an increased survival as compared with control
gated the efficiency of an HSVtk gene therapy for the treat- rats and with those treated with a single cycle of retrovirus
ment of peritoneal carcinomatosis induced in syngeneic producing cells plus ganciclovir. However, only a few ani-
rats by DHD/K12 colon carcinoma cells. In this setting, the mals remained tumor-free after day 180. There was no dif-
efficiency of two different retrovirus producing cell lines ference between the two producing cell lines in any of the
(GP+AmEnv12 and FLYA13) was compared. Rats treated experiments. RT-PCR demonstrated a faint expression of
with a single injection of retrovirus producing cells followed the tk transgene in the liver, spleen, epiploon, bowels and
by a 5-day course of ganciclovir treatment showed an the lung of the animals injected with the HSVtk producing
increased survival as compared with control animals. Ani- cells, reflecting most likely the transduction of only a limited
mals treated with three injections of producing cells, each number of cells.
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Introduction
Peritoneal dissemination is a common clinical situation
in patients suffering from ovarian or digestive primary
neoplasms.1 Surgical resection of extensive peritoneal car-
cinomatosis is impossible. Moreover, most of these can-
cers, including colorectal carcinoma, are poorly reactive
to systemic chemotherapy.2
Suicide gene therapy consists in the intracellular deliv-
ery of a gene coding for an enzyme which transforms a
prodrug into a cytotoxic product.3,4 Thymidine kinase
from the herpes simplex virus type 1 (HSVtk) is the best
studied and most used suicide gene. It can efficiently
phosphorylate nucleoside analogs such as ganciclovir
(GCV) into monophosphorylated molecules. Phosphoryl-
ation by cellular kinases leads then to the formation of
the cytotoxic ganciclovir-triphosphate which is incorpor-
ated into DNA and inhibits DNA polymerase.5–7 Of great
therapeutic interest, untransduced adjacent cells are also
sensitive to the GCV-triphosphate cytotoxic effect
(‘bystander effect’).8–14
For in vivo transduction of HSVtk gene, retroviral vec-
tors have been successfully used in numerous tumor
models.15–17 In this strategy, the requirement of active
DNA synthesis for retrovirus replication limits the HSVtk
gene delivery to proliferating tumor cells. Such an
approach is currently used in several clinical trials,
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mostly for the treatment of brain tumors18,19 and more
recently for the treatment of cancers disseminated in
anatomical cavities.20,21
We and others have recently demonstrated the
efficiency of an HSVtk-mediated gene therapy for perito-
neal carcinomatosis induced by colorectal adenocarcin-
oma cells in a syngeneic immunocompetent animal
model.22,23
The aim of the present work was to study the thera-
peutic effect of retrovirus-mediated transfer of the HSVtk
gene in the same model of peritoneal carcinomatosis
induced by colorectal adenocarcinoma cells in syngeneic
rats. In these experiments, we demonstrated an increase
survival of the animals treated with multiple intraperi-
toneal injections of HSVtk retrovirus producing cells
followed each time by a GCV treatment.
Results
Retrovirus producing cell lines
In this report, two different packaging cell lines were
used, GP+AmEnv12 and FLYA13. The FLYA13 cell line
has been described as a highly efficient retrovirus pro-
ducing line, generating high titers of retroviruses resist-
ant to inactivation by human serum.24 We developed a
HSVtk retrovirus producing cell line FLYA13-TK by
transfection of a retroviral vector, derived from the
Moloney murine leukemia retrovirus (Mo-MuLV). The
second HSVtk retroviral producer cell line GP+AmEnv12-
TK was a generous gift from Dr C-M Calberg (Laboratory
of Virology, University of Lie`ge, Belgium). Using G418
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particles produced by both cell lines and reproducibly
found a titer of 1 · 106 p.f.u./ml for GP+AmEnv12-TK
cells and 2 · 105 p.f.u./ml for FLYA13-TK cells.
Survival of rats after a single i.p. injection of retrovirus
producing cell lines
We investigated the efficiency of HSVtk-based gene ther-
apy in a model of peritoneal carcinomatosis induced by
DHD/K12 colorectal adenocarcinoma cells in syngeneic
BD-IX rats. As previously reported, ganciclovir treatment
of animals injected i.p. with stably transfected DHD/K12-
TK cells allowed a significant reduction of tumor volume,
as well as prolonged survivals.22
BD-IX rats i.p. injected at day 0 with 106 DHD/K12
cells developed a peritoneal carcinomatosis before day 14
and died of peritoneal dissemination within 60 days.22
HSVtk retrovirus producing cells (GP+AmEnv12-TK or
FLYA13-TK) were injected at day 9 and a GCV (150
mg/kg) treatment was administered once daily from day
14 for 5 days (Figure 1a, 10 animals for each group). Sim-
ultaneously, a control goup (five animals) which had also
been injected with HSVtk retrovirus producing cells, was
treated according to the same protocol with 10 ml of
HBSS (Hank’s balanced salt solution). The animals
injected with the HSVtk retrovirus producer FLYA13-TK
cells and treated with HBSS died between days 42 and
51 (median survival: 48 days) (Figure 1b). Animals
Figure 1 Survival of rats after a single i.p. injection of retrovirus producing FLYA13-TK or GP+EnvAm12-TK cells and treatment with GCV. (a)
Protocol for i.p. single delivery of HSVtk retrovirus producing cells and GCV treatment. The rats were i.p. injected with 106 DHD/K12 cells at day
0. The HSVtk retrovirus producing cells FLYA13-TK or GP+EnvAm12-TK were i.p. injected at day 9. For the GCV-treated group, the treatment started
at day 14 for 5 days with 150 mg/kg of GCV once daily, while at the same time, a control group was injected with 10 ml of HBSS once daily. (b)
Survival curves: 10 or five animals were respectively monitored in the GCV and in the control groups. In the FLYA13-TK and GP+EnvAm12-TK
GCV-treated groups, one rat was still alive and tumor-free at day 240.
injected with HSVtk retrovirus producer FLYA13-TK cells
and treated with GCV showed a significantly prolonged
survival as compared with the HBSS-treated animals
(log-rank test, P , 0.01; median of survival, 52 days). The
five animals injected with HSVtk retrovirus producer GP-
AmEnv12-TK cells and treated with HBSS died between
days 42 and 51 (median survival, 45 days) (Figure 1b).
Animals injected with HSVtk retrovirus producer
GP+AmEnv12-TK cells and treated with GCV showed a
significantly prolonged survival as compared with the
HBSS-treated animals (log-rank test, P , 0.05; median of
survival, 55 days). However, in each of the GCV-treated
group, only one animal out of 10 showed a long survival
and was free of tumors at day 240 (Figure 1b). We did
not observe any significant difference between the results
obtained after treatment with the different retrovirus
producing cell lines.
Survival of rats after three i.p. injections of retrovirus
producing cell lines
To improve the efficiency of the suicide gene treatment,
BD-IX rats were i.p. injected at day 0 with 106 DHD/K12
cells and the HSVtk retrovirus producing cells
(GP+AmEnv12-TK or FLYA13-TK) were injected at days
9, 18 and 25. For the treated groups (10 animals for each
group), daily 150 mg/kg GCV i.p. injections were perfor-
med from day 14 to 17, from day 21 to 24 and from day
28 to 32 (Figure 2a). At the same time, control groups
Retrovirus-mediated tk gene therapy for peritoneal carcinomatosis
F Princen et al
1056
Figure 2 Survival of rats after three i.p. injections of HSVtk retrovirus producing FLYA13-TK or GP+EnvAm12-TK cells. Each injection was followed
by a GCV treatment. (a) Protocol for i.p. multiple delivery of HSVtk retrovirus producing cells lines and GCV treatment. Each group was i.p. injected
with 106 DHD/K12 cells at day 0. The HSVtk retrovirus producing FLYA13-TK or GP+EnvAm12-TK cells were i.p. injected at day 9, 18 and 25. For
the GCV-treated group, the first treatment was administered from day 14 to 17, the second from day 21 to 24 and the third from day 28 to 32, with
150 mg/kg of GCV once daily. At the same time, the control group received 10 ml of HBSS once daily. (b) Survival curves: 10 or five animals were
respectively monitored in the GCV and in the control groups. In both GCV-treated groups FLYA13-TK and GP+EnvAm12-TK, one rat was still alive
and tumor-free at day 240.
(five animals in each group) were injected with the tk pro-
ducing cells and treated according to the same protocol
with 10 ml of HBSS (Hank’s balanced salt solution). The
five animals injected with HSVtk retrovirus producing
FLYA13-TK cells and treated with HBSS died between
day 49 and 55 (median survival, 51 days) (Figure 2b).
Animals repeatedly injected with HSVtk retrovirus pro-
ducing FLYA13-TK cells and treated with GCV showed
a significantly prolonged survival as compared with the
HBSS-treated animals (log-rank test, P , 0.01; median
survival, 70 days). The five animals injected with HSVtk
retrovirus producer GP-AmEnv12-TK cells and treated
with HBSS died between day 52 and 59 (median survival,
55 days) (Figure 2b) while animals repeatedly injected
with the same producing cells and treated with GCV
showed a significantly prolonged survival (log-rank test,
P , 0.001; median survival, 73 days). However, in each
of the GCV-treated group, only one animal out of 10
showed a long survival and was free of tumors at day
240 (Figure 2b). In these conditions, we did not observe
any difference between the groups of animals treated by
the two retrovirus producing cell lines.
We compared the outcome of animals treated with a
single or with three cycles of retrovirus-mediated tk gene
transfer plus GCV. As shown in Figure 3, the animals
which received three injections of FLYA13-TK or
GP+AmEnv12-TK producing cells followed by GCV had
a significantly better survival than the animals treated
with a single course of producing cells plus GCV
(P , 0.05).
In vivo distribution of HSVtk retroviruses after
intraperitoneal injection of HSVtk retrovirus producing
cells
The biodistribution of HSVtk retroviruses following
single or multiple intraperitoneal injections of HSVtk
retrovirus producing cells (GP+AmEnv12-TK or FLYA13-
TK) is an important consideration for the safety of the
treatment.
The expression of HSVtk mRNA in various samples of
organs from differently treated rats was investigated by
RT-PCR followed by Southern blotting and tk-DNA
probe detection. The levels of tk mRNA were evaluated
in various tissues of peritoneal carcinomatosis bearing
rats which received either a single or a triple i.p. adminis-
tration of HSVtk producing cells. In these experiments,
two animals were analyzed for each condition.
After a single i.p. administration of HSVtk producing
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Figure 3 Comparison of single versus multiple cycles of tk-retrovirus
infections plus GCV treatment. Survival curves were established for the
20 animals treated with a single injection of retrovirus producing cells
(FLYA13-TK or GP+EnvAm12-TK) and for the 20 animals treated with
three cycles of TK-retrovirus plus GCV.
cells (GP+AmEnv12-TK or FLYA13-TK), a weak but
detectable expression of the transgene was detected in
liver, spleen, epiploon, bowels and lungs (Figure 4a).
When compared with the signal (Figure 4a, lane +)
obtained with DHD/K12 cells stably transfected with the
tk gene, those observed in the different tissues indicated
that only a small proportion of cells were transduced by
the HSVtk retrovirus. However, a strong expression of
the tk transgene was detected in the epiploon of one of
the animals injected with Gp+AmEnv12-TK cells (Figure
4a, lower panel).
Similarly, after three i.p. administrations of HSVtk pro-
ducing cells (GP+AmEnv12-TK or FLYA13-TK), the
expression of the transgene was also detected by RT-PCR
in the same organs (Figure 4b). The HSVtk expression
was clearly higher after multiple injections of the produc-
ing cells than after a single injection (compare Figure 4a
and b) but remained much lower than that observed in
control tk expressing DHD/K12 cells (Figure 4b, lane +)
indicating that only a small proportion of the cells from
these tissues had captured the transgene.
Discussion
Peritoneal carcinomatosis remains a major clinical prob-
lem as neither surgery nor chemotherapy can eradicate
tumor cells disseminated in the peritoneal cavity. Novel
therapeutic approaches are thus required to treat these
tumors which constitute a suitable model for gene ther-
apy. Indeed, intraperitoneal administration of viruses or
virus producing cells should confine gene transduction
to the peritoneal cavity. We therefore investigated
whether a tk-based suicide gene therapy could treat per-
itoneal carcinomatosis induced by DHD/K12 colorectal
adenocarcinoma cells in syngeneic BDIX rats.
In this model, rats i.p. injected with DHD/K12 cells
developed a macroscopic peritoneal carcinomatosis
within 12 days. The animals were then injected once or
three-fold with retrovirus producing cells, each adminis-
tration being followed, 3 to 5 days later to allow tk gene
expression, by a GCV treatment.
The efficiency of in vivo retrovirus-mediated gene
delivery depends on virus titer and on virus stability.
Therefore, we chose to compare the efficiency of two
retrovirus producing cell lines. In our hands, the retro-
virus titer obtained with the FLYA13-TK cells was lower
than with the GP+AmEnv12-TK cells, although the
FLYA13 has been reported to generate high titers of retro-
viruses.24 In vivo, we did not observe any difference in
the outcome of animals treated with one cell line or the
other. This could mean that the virus titer does not influ-
ence the therapeutic benefit in our model or that the
lower titer observed with the FLYA13-TK cells is com-
pensated by the production of more stable viruses. Alter-
natively, the killing of allogeneic tumor cells might
induce a local inflammatory reaction and could partici-
pate in the bystander effect. In this hypothesis, one could
imagine that such a nonspecific stimulation of the
immune system might be more important with human
FLYA13 cells than with murine GP+AmEnv12 cells and
that such a difference could partially explain the
observed results. Ongoing experiments comparing the
efficiency of liposomes and retrovirus producer cells will
help to define the putative role of an immune bystander
effect generated by the killing of allogeneic producer
cells.
Rats treated with a single injection of producing cells
followed by a 5-day course of GCV showed an increased
survival when compared with control animals. However,
it is clear from a number of experiments that a single
injection of producing cells would lead to the transduc-
tion of only a small proportion of tumor cells. Therefore,
we repeated three times the injection of producing cells
followed each time by a GCV treatment, hoping to
improve the efficacy of the treatment. In these conditions,
animals again showed an increased survival as compared
with control animals. Moreover, their survival curves
were better than those observed after a single cycle.
These data thus demonstrated that repeated cycles of pro-
ducing cell injections followed by GCV treatments were
more efficient than a single cycle and that such an
approach will have to be considered for the design of
future clinical trials.
Our results compare favorably with other data
obtained after in vivo delivery of the HSVtk gene. Indeed,
several authors reported a poor efficiency of such an
approach and questioned whether the suicide gene alone
would be able to improve the outcome of animals or
patients suffering from cancers.25–27 Several reasons could
account for our favorable data. First, the peritoneal cavity
should allow a large distribution of the retrovirus pro-
ducing cells and an efficient infection of a number of
small size peritoneal tumor nodes while producing cells
injected in a solid tumor would only be able to deliver
the gene to a low number of neighboring tumor cells.
Secondly, the DHD/K12 cells could demonstrate a very
efficient bystander effect, allowing the diffusion of the
phosphorylated GCV from cell to cell through the gap
junctions. Our previous in vivo data showed that i.p.
injections of 20% of tk expressing DHD/K12 cells com-
bined with untransfected DHD/K12 cells allowed an
increased survival after GCV treatment.22 Also, as our
model is based on immunocompetent animals, an
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Figure 4 tk Gene expression in various organs following single or multiple i.p. injections of HSVtk retrovirus producing cells. The expression of HSVtk
mRNA in various organs was investigated by RT-PCR followed by Southern blotting revealed by a tk probe after one or three administrations of HSVtk
producing cells into the peritoneal cavity of rats with established peritoneal carcinomatosis. Two animals were studied for each condition. (a) Animals
received a single i.p. injection of HSVtk retrovirus producing FLYA13-TK or GP+EnvAm12-TK cells. Samples of tissue from different organs were
collected 5 days after injection of producing cells. Total RNA was isolated and RT-PCR were performed with primers designed to amplify the HSVtk
message (593 bp). The PCR products were analyzed by Southern blotting probed with a specific 32P labeled tk DNA probe. The organs analyzed and
the cell lines injected are indicated in the Figure. (b) Animals received three injections of HSVtk retrovirus producing FLYA13-TK or GP+EnvAm12-
TK cells. At day 28, 3 days after the last injection of producing cells, the organs were harvested and total RNA was isolated and analyzed as in (a)
for tk gene expression. In a and b, lane (- ) shows the negative control (PCR performed on water) and lane (+) shows the RT-PCR performed on the
DHD/K12-TK stably transfected cells. The presence of HSVtk mRNA was detected in all the organs analyzed.
immunological antitumor reaction could have played a
role in delaying tumor progression or even in eradicating
the tumor in a few animals after the HSVtk/GCV treat-
ment. Other authors had previously demonstrated an
immune response following HSVtk gene therapy.13,28–32
However, despite these favorable results, only 10% of
the treated animals were still alive and tumor-free at day
240, confirming that the tk gene alone will only rarely
eradicate established solid tumors. In the future, it will
thus be necessary to combine the tk gene or other suicide
genes therapy system with additional therapeutic
approaches acting by other mechanisms on the cancer
cells.23,26
The distribution of the tk mRNA in the organism was
studied by RT-PCR. In the peritoneal cavity itself the dis-
tribution appeared to be quite heterogenous as one sam-
ple from the epiploon showed a high expression of the
transgene while other samples demonstrated only a faint
expression (Figure 3). This is quite consistent with the
data obtained in our laboratory with a LacZ retrovirus.
After i.p. injection of LacZ retrovirus producing cells, a
few peritoneal tumor nodes showed a high expression
of the transgene while others had apparently remained
untransduced or poorly transduced (data not shown).
The strong signal observed on Figure 3a is probably
related to one of these highly transduced tumor nodes.
This heterogenous distribution of the transgene in tumor
nodes is another argument in favor of repeated injections
of retrovirus producing cells.
RT-PCR analysis demonstrated a low expression of the
transgene in several intra- and extra-abdominal organs.
This observation was expected given the high number of
injected producing cells and the communications existing
between the peritoneal cavity and the rest of the organ-
ism. Similar observations had previously been reported
with adenoviruses.33 However, a comparison of the tk
mRNA expression observed in these organs with the
level of expression detected in stably transfected
DHD/K12 cells indicates that only a very small number
of cells have probably been transduced in these organs.
Therefore, any significant toxicity should not be expected
after such a treatment and was not observed in our
experiments. However, the levels of the expression in
these organs is higher after three injections of retrovirus
producing cells than after a single one, indicating that, if
repeated producing cells injections increase the efficacy
of tk gene therapy, they also might increase the risk of
toxicity.
Materials and methods
Cell lines and retroviral vector
DHD/K12/Prob cells were cultured in DMEM-modified
Dulbecco’s medium (Life Technologies, Gaithersburg,
MD, USA) supplemented with 5% fetal bovine serum
(FBS), 1% glutamine 200 mm, 1% Hepes 1 m, 1% arginine
0.55 mm and antibiotics.
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derived from murine NIH3T3 fibroblasts34 and the
FLYA13 line derived from human HT1080 fibrosarcoma
cells24 (FLYA13 was obtained from European Collection
of Cell Cultures, Salisbury, UK). GP+EnvAm12 and
FLYA13 cells were cultured in DMEM-modified Dulbec-
co’s medium (Life Technologies) supplemented with 10%
fetal bovine serum (FBS) (Life Technologies), antibiotics
and 1% glutamine 200 mm (Life Technologies).
The retroviral vector, derived from a murine retrovirus
(Mo-MuLV), was a generous gift from Dr C-M Calberg
(Laboratory of Virology, University of Lie`ge, Belgium).
This vector contains the neomycin resistance gene driven
by the first LTR and the HSV1-tk gene driven by a
SV40 promoter.
Animal treatment and in vivo transduction
For single in vivo transduction, BD-IX rats were injected
i.p. at day 0 with 106 DHD/K12 tumoral cells. On day
9, the animals were i.p. injected with 30 · 106 retrovirus
producing cells per animal (FLYA13-TK cells or
GP+EnvAm-TK cells) (Figure 1a). They were then separ-
ated in two groups and treated for 5 days, starting at day
14, either by i.p. injections of GCV (150 mg/kg) diluted
in Hank’s balanced salt solution (HBSS; Gibco BRL) or of
the HBSS buffer alone.
For triple in vivo transductions, BD-IX rats were
injected i.p. at day 0 with 106 DHD/K12 tumoral cells.
The animals received three intraperitoneal injections of
30 · 106 retrovirus producing cells (FLYA13-TK cells or
GP+EnvAm-TK cells) at days 9, 18 and 25 (Figure 2a).
They were separated in two groups and treated either
with GCV (150 mg/kg from day 14 to 17, from day 21
to 24 and from day 28 to 32) or with HBSS alone accord-
ing to the same schedule (Figure 2a).
Statistics
Kaplan–Meier curves were established for each group
and survivals were compared with the log-rank test.
RT-PCR for HSVtk expression
tk Gene expression in various organs after a single or
three-fold in vivo transduction was investigated by RT-
PCR followed by Southern blotting. Tissue samples from
various organs (liver, bowels, lung, spleen and epiploon)
were collected 5 days after the injection of producing cells
(day 14) for the single transduction group (two animals)
and 3 days after the last injection (day 28) for the triple
transduction group (two animals).
Total cellular RNA was extracted by Tripure reagent
(Boehringer Mannheim, Mannheim, Germany). One
microgram of RNA was reverse transcribed (Superscript
II; Life Technologies, Gaithersburg, MD, USA) with a
specific tk-3¢ primer (5¢ -ACAGGGTAAATAACGTGTC-
3¢ ). After purification by filtration on a spin column
(GlassMax DNA Isolation Spin Cartridge System; Life
Technologies), the cDNA product was amplified with the
tk primers 5 ¢ -ATGGCTTCGTACCCCTG-3 ¢ and 5 ¢ -
AAGGTCGGCGGGATGAG-3 ¢ . A 35 cycle amplification
was performed (denaturation at 95° C for 1 min,
annealing at 50 ° C for 1 min, and elongation at 72° C for
2 min) followed by a 4 min final elongation at 72 ° C. The
RT-PCR products (593 bp) were transferred on a nylon
membrane (Quiabrane; Qiagen, Hilden, Germany) and
analyzed by Southern blotting. The tk-DNA probe
was a 32P randomly labeled RT-PCR product (593 bp)
amplified from stably transfected DHD/K12-tk cells.
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